Connect with us

Technology

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Published

on

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster.

BETHESDA, Md. and BOSTON and ROLLE, Switzerland, April 8, 2025 /PRNewswire/ — Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. As part of this collaboration, Precision for Medicine will integrate the SOPHiA DDM™ Platform for biomarker discovery, clinical trial assays (CTAs), and advanced algorithms to expand clinical trial capabilities. This partnership will further enhance service offerings and provide biopharma companies with tools to accelerate clinical trial design, patient stratification, and data analysis.

Biopharma clients can accelerate drug development with a seamless solution for data analysis and clinical support.

Through this partnership, Precision for Medicine will leverage the SOPHiA DDMTM Platform’s advanced AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical data. This capability will allow biopharma companies to identify and target the most appropriate patient populations for clinical trials, accelerating biomarker discovery and improve diagnostic capabilities. This is crucial for precision medicine efforts in oncology, rare diseases, and genetic disorders, where understanding the specific genomic characteristics of each patient may enable more targeted therapies.

Additionally, MSK-ACCESS® powered with SOPHiA DDMTM, an innovative liquid biopsy test being deployed globally with the support of AstraZeneca, will be made available as a Precision for Medicine service for biopharma clients. Data generated by this genomically rich, globally deployed test will enable retrospective clinical trial data analysis and improve patient stratification. This capability allows biopharma companies to refine and optimize their clinical trial designs by better understanding how patients responded to previous treatments. This evidence-based approach can help companies fine-tune their drug development strategies, improve patient recruitment for trials, and gain deeper insights into the efficacy of therapies in real-world settings.

“We’re thrilled to partner with SOPHiA GENETICS to integrate the SOPHiA DDMTM Platform and integrate MSK-ACCESS® powered with SOPHiA DDMTM into our offering, providing biopharma companies with the tools to accurately identify the right patient populations for enrollment into clinical trials,” said Darren Davis, PhD, Senior Vice President Precision for Medicine. “By leveraging AI-powered algorithms and machine learning, we can pinpoint biomarkers and genomic signatures that enable more efficient, targeted trials and improve therapeutic efficacy. This ultimately helps speed up patient enrollment, reduce trial costs, and bring therapies to market faster.”

Through this partnership, Precision for Medicine will provide wet lab services, alongside data analysis and clinical trial support, offering biopharma companies expanded capabilities under one umbrella. This integrated approach allows clients to rely on a single solution provider, with Precision for Medicine and SOPHiA GENETICS working together to deliver seamless end-to-end support for their drug development programs.

“Our collaboration with Precision for Medicine enables us to expand the reach and impact of our SOPHiA DDMTM Platform and deliver real-time actionable insights across the clinical trial continuum,” said Ross Muken, President at SOPHiA GENETICS. “By combining our AI-powered Platform with Precision for Medicine’s cutting-edge clinical trial solutions, we can deliver comprehensive, data-driven capabilities to biopharma companies, accelerating the path to market for precision therapies.”

Precision for Medicine’s established clinical trial expertise, including biomarker testing and wet lab services, combined with SOPHiA GENETICS’ AI-based genomic analysis tools, creates a powerful comprehensive solution for biopharma companies. Biopharma clients can now accelerate drug development with a seamless solution for data analysis and clinical support, enabling more efficient progression from preclinical research to market readiness. This collaboration provides a competitive edge, allowing clients to bring innovative therapies to patients faster and improve market positioning in the highly competitive biopharma landscape.

This exciting partnership is a key driver of innovation in precision medicine, providing biopharma companies with tools to better understand patient genomic makeup and develop personalized treatments for complex diseases. The collaboration enables biopharma companies to tailor treatments based on specific genomic profiles, with the potential to enhance outcomes, patient satisfaction, and the market value of their products. This patient-centric approach aims to fuel breakthroughs in oncology, rare diseases, and other high-unmet-medical areas.

About Precision for Medicine

Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,400 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit PrecisionForMedicine.com.

Contact

Brad Epstein

Brad.epstein@precisionformedicine.com 

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Kelly Katapodis

media@sophiagenetics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-for-medicine-partners-with-sophia-genetics-to-expand-biopharma-services-with-the-sophia-ddm-platform-and-its-liquid-biopsy-capabilities-302422644.html

SOURCE Precision for Medicine

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Truemed and Highmark Benefits Administration Partner to Expand Access to Root‑Cause Healthcare and Enable Employers to Reach Benefits Goals

Published

on

By

AUSTIN, Texas, May 1, 2026 /PRNewswire/ — Truemed, the leading platform enabling qualified health purchases with HSA and FSA dollars, today announced a strategic partnership with Highmark Benefits Administration, a trusted provider of comprehensive, compliance‑driven solutions committed to providing A+ benefits administration services to clients nationwide.

The partnership aligns two organizations focused on delivering innovative, cost-effective solutions that help clients achieve business goals while empowering employees to use their benefits confidently and proactively. By integrating Truemed’s medically-necessary qualification process with Highmark’s service‑driven administrative infrastructure, employers can offer a broader range of eligible health interventions while maintaining clarity, compliance, and operational efficiency.

Through this collaboration, eligible Highmark participants can use pre‑tax HSA and FSA funds on evidence‑based, root‑cause health solutions— including fitness and movement programs, nutrition and supplement options, stress‑management tools, and other medically‑necessary interventions designed to help employees proactively improve their health.

“At Highmark Benefits Administration, we understand that managing employee benefits and plan compliance can be a daunting task, but it doesn’t have to be,” said Dan Bearden, Founder and Director of Highmark. “Partnering with Truemed expands what’s possible with HSA and FSA dollars while maintaining the clarity and compliance confidence our clients rely on. We’re excited to help participants access more meaningful health solutions.”

“Highmark has built a reputation for exceptional service and operational excellence,” said Justin Mares, CEO of Truemed. “This partnership builds on that foundation by giving eligible participants access to root‑cause health interventions that have been shown to improve health outcomes and chronic condition management. Together, we’re helping employers offer benefits that are simple, compliant, and truly impactful.”

Learn more at: truemed.com/a/highmark

Truemed is for qualified customers. See terms at truemed.com/disclosures.

About Truemed

Truemed partners with consumer health brands and benefits administrators to enable HSA and FSA payments for root‑cause healthcare expenses. Through licensed practitioner review and IRS‑aligned documentation, Truemed helps qualified individuals invest in medically necessary products and services using pre‑tax dollars. Learn more at truemed.com.

About Highmark Benefits Administration

Highmark Benefits Administration provides comprehensive, cost‑effective benefits administration services designed to simplify complexity and support employer goals. With expertise in enrollment and eligibility management, COBRA administration, FSA/HSA/HRA programs, compliance reporting, carrier billing, and employee communication, Highmark delivers exceptional service backed by modern technology solutions. Learn more at highmarkbenadmin.com.

Media Contact:
Tom Dahl
tom@truemed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/truemed-and-highmark-benefits-administration-partner-to-expand-access-to-rootcause-healthcare-and-enable-employers-to-reach-benefits-goals-302760163.html

SOURCE Truemed

Continue Reading

Technology

DistrictWON’s uReport Partners with KOIN to Usher Back Local Sports Coverage to Every Community

Published

on

By

PORTLAND, Ore., May 1, 2026 /PRNewswire/ — KOIN 6 is proud to announce a groundbreaking partnership with uReport, bringing comprehensive, community-driven sports coverage to every high school across the entire metro Portland and southwestern Washington markets.

Through this initiative, KOIN is offering uReport, a human-powered, AI-assisted platform widely endorsed across high schools and colleges nationwide, fully-funded to all high schools in the region. uReport is ISTE EdTech Index Approved and listed in the ISTE Learning Technology Directory, a vetted resource used by educators to identify high-quality digital learning tools.

This partnership empowers schools, students, and communities to create and share stories, highlights, and updates across all sports, while amplifying that content across KOIN.com. uReport is already endorsed by leading organizations including the National Interscholastic Athletic Administrators Association, College Sports Communicators and other groups representing over 17,000 high schools and colleges.

“Local sports coverage has historically reached the biggest schools and the biggest games. uReport flips that. Every school in our market — from the 6A powerhouse to the 1A program with 80 kids — now has a dedicated platform on KOIN.com,” said Tom Keeler, Vice President & General Manager of KOIN.

Key benefits for each school & community include:

A dedicated content platform for every school.The ability to cover every game, every sport at every level and include unlimited pictures and videos.Every school will also be featured on KOIN.com, allowing all schools to consistently make the news!Schools also distribute content onto their own social channels, creating an amazing content library Real-world training for student journalism and responsible use of AI in storytellingA free fan-powered mobile app for real-time contributions from the communityFull customer support for the platform, all year. 

Check out a quick explainer video here: KOIN – Supercharging Your Coverage

KOIN will host three short webinars for Portland market school administrators to learn more. Any administrator is encouraged to participate (administrator, teacher, coach or other, click below to attend):
Tuesday 5/5: 9am PT
Wednesday 5/6: 8am PT
Thursday 5/7: 12pm PT
Schools can self-start and sign-up right now to cover spring events and continue to have access for the entire 2026–27 academic year. Self-start sign-up is easy here: www.ureport.com/koin

For more information, contact uReport Director of Customer Success, Dan McGrath: 216-647-3857; dmcgrath@districtwon.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/districtwons-ureport-partners-with-koin-to-usher-back-local-sports-coverage-to-every-community-302760179.html

SOURCE DistrictWON

Continue Reading

Technology

Fuutura Outlines Architecture Built for the Cross-Border Stablecoin Corridors the IMF Now Tracks

Published

on

By

As the IMF’s April 2026 Global Financial Stability Report calls for enhanced regulatory oversight of cross-border stablecoin flows to emerging markets, Fuutura’s compliance-first architecture across identity, payments, and trading is built to support exactly this kind of regulatory oversight

PANAMA CITY, Panama, May 1, 2026 /PRNewswire/ — Fuutura, a blockchain infrastructure company building a compliance-first financial ecosystem for the global market, today set out its position on rising cross-border stablecoin flows to emerging markets, following the IMF’s call for enhanced regulatory oversight in its April 2026 Global Financial Stability Report.

 

 

The IMF’s findings reflect a structural shift in how money moves across emerging economies. Cross-border flows of the two largest dollar-pegged stablecoins, Tether and USD Coin, rose from approximately $12 billion in early 2020 to $316 billion by early 2025, outpacing flows of Bitcoin and Ethereum. A significant share of those flows has been directed toward emerging markets, with cumulative net inflows accelerating since late 2023. The IMF’s concern is that rapid stablecoin adoption in emerging markets, absent appropriate regulation and backstops, could lead to currency substitution, weaken the transmission of monetary policy, increase capital flow volatility, and create challenges for capital flow management measures.

The IMF report also acknowledges that stablecoins, with adequate regulation, could offer improved settlement efficiency, faster cross-border payments, increased competition in the payment space, and broader access to digital finance. The same flows that warrant enhanced oversight also reflect genuine demand for financial services that legacy infrastructure has consistently failed to deliver in emerging markets.

Fuutura is being built to make both possible at once. A compliance by design approach facilitates the very regulatory oversight the IMF is advocating. That same architecture allows the platform to serve users in markets unreached by legacy financial infrastructure. What that looks like in practice is best described by the people who have built it.

“The IMF’s findings lay bare something that anyone working in cross-border financial services across emerging markets has been seeing for years. The flows are real, the demand is structural, and the existing infrastructure has not been built to give regulators the kind of visibility they need to do their work properly. That is the gap our infrastructure is built to address, across cross-border payments, identity verification, and the trading layer that connects users to the global financial system. Compliance is not something we have layered on top of an existing platform. It is part of how the system functions at every level.”

Ellis McGrath, Co-founder and Chief Technology Officer, Fuutura

The architectural choice that defines Fuutura is the integration of compliance at a foundational level. Most digital asset platforms operate perimeter compliance, with KYC and AML conducted at onboarding and transaction monitoring sitting on top of an existing technology stack. Fuutura’s design records verified KYC and AML attestations on-chain and ties them to the user’s wallet, so that every interaction with the platform is gated by the presence of that attestation at the smart contract level. This applies across the entire ecosystem. Whether a user is opening a wallet, executing a trade on the exchange, or moving funds across borders, the same compliance design governs every interaction. The result is infrastructure where compliance is enforceable on every transaction and auditable by regulators at the on-chain level.

“The platforms that earn regulators’ trust will be the ones that make their work easier. The IMF’s call for proportionate monitoring of stablecoin flows reflects a broader truth about the relationship between innovators and regulators in this industry. Architecture that is open to inspection by default. A company posture that welcomes the questions responsible oversight requires. We believe the future of digital finance depends on builders and regulators working together, and we have designed Fuutura to support that relationship across every product on the platform.”

Oliver Cook KC, Co-founder and Chief Legal Officer, Fuutura

Fuutura is building for a market where existing financial infrastructure has consistently failed to deliver. The cross-border stablecoin corridors identified by the IMF are one part of that market. The broader scope is the millions of people and businesses across emerging economies who require digital identity, secure custody, and access to global financial markets in a single connected environment. The company’s launch marks the beginning of a phased rollout, with further ecosystem development planned as the platform scales across the markets it was designed to serve.

About Fuutura

Fuutura is a blockchain infrastructure company building a compliance-first financial ecosystem facilitating participation in the global financial system from underserved markets with a focus on the Global-South. The platform combines digital identity verification, a wallet, and a trading exchange into one unified ecosystem, giving users access to crypto and tokenised real-world assets through a single environment. Fuutura is pursuing licensing in multiple jurisdictions. Built with KYC and AML integrated at an architectural level, Fuutura is designed to be open to regulatory oversight by design. Fuutura is building infrastructure to extend digital finance to markets that legacy banking has not reached.

Media Contact
Fuutura
pr@fuutura.com

Forward-Looking Statements and Risk Disclosures

Digital asset risk. Digital assets are high-risk and their value may fall as well as rise. Trading digital assets involves significant risk and may not be suitable for all investors. Past performance is not a reliable indicator of future results.

Forward-looking statements. This press release contains forward-looking statements regarding Fuutura, its technology, products, business plans and future conduct, including statements relating to the phased rollout of the ecosystem, regulatory engagement and licensing outcomes, geographic expansion, and market ambitions. Forward-looking statements are identifiable by words such as “building,” “plans,” “intends,” “expects,” “designed to,” “anticipates” and similar expressions, as well as by statements regarding future outcomes, ambitions or strategic direction.

Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual outcomes to differ materially from those expressed. These include, without limitation, changes in the regulatory environment across jurisdictions; the availability and timing of licensing or authorisation; developments in digital asset markets; technological and cybersecurity risks; operational risks; counterparty and third-party risks; the pace of product development; and other factors beyond Fuutura’s control.

No offer or advice. Nothing in this press release constitutes an offer to sell, a solicitation to purchase, investment advice, or a recommendation in respect of any digital asset, crypto-asset, token, security, or financial product or instrument. Fuutura’s products and services may not be available in all jurisdictions and may be subject to regulatory restrictions. Access to Fuutura’s platform is restricted to residents of jurisdictions where its services are permitted.

No duty to update. Fuutura undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

This release is not for distribution in the United States, the United Kingdom, the European Union, or in any other jurisdiction where such distribution would be unlawful.

Photo:  https://mma.prnewswire.com/media/2970890/Fuutura.jpg
Logo:   https://mma.prnewswire.com/media/2965342/5949163/Fuutura_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/fuutura-outlines-architecture-built-for-the-cross-border-stablecoin-corridors-the-imf-now-tracks-302760188.html

Continue Reading

Trending